The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.

Ian J Neeland Bjorn EliassonTakatoshi KasaiNikolaus Marx Bernard Zinman Catherine M Viscoli Christoph WannerIsabella ZwienerBrian S WojeckHenry K YaggiOdd Erik Johansennull null

Published in: Diabetes care (2020)

In EMPA-REG OUTCOME, participants with OSA had greater comorbidity and higher frequency of CV and renal events. Empagliflozin had favorable effects on risk factors and CV and renal outcomes regardless of preexisting OSA and may also reduce the risk for new-onset OSA.

Keyphrases

obstructive sleep apnea
positive airway pressure
risk factors
sleep apnea
clinical trial
phase iii
randomized controlled trial
phase ii